Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-16-013058
Filing Date
2016-02-10
Accepted
2016-02-10 20:30:40
Documents
2
Period of Report
2016-02-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6110
2 EX-24 DOCUMENT attachment1.htm EX-24 2326
  Complete submission text file 0000899243-16-013058.txt   10694
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37695 | Film No.: 161407600
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37695 | Film No.: 161407601

Mailing Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 617-225-0096
PROTEOSTASIS THERAPEUTICS, INC. (Issuer) CIK: 0001445283 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
SIC: 2834 Pharmaceutical Preparations